| Client |
Mid-market Private Equity firm in Western Europe |
| Situation |
Client had recently acquired a CRO focusing on Phase 1-3 clinical trials for Pharma and Biotech customers. They were keen to augment the portfolio company’s capabilities by acquiring complementary assets in the US and also to broaden the services offering |
| Our approach |
We leveraged our IP to generate a comprehensive database of CROs offering services that could be considered complementary to the portfolio company. Based on our research, we identified, evaluated and prioritized over 200 add-on targets and initiated contact with selected potential targets. |
| Results |
Our client (mid-market private equity fund), managed to close 2 add-on deals for their CRO portfolio company, within a period of one year. |
